Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Galectin Therapeutics Inc (NASDAQ: GALT).

Full DD Report for GALT

You must become a subscriber to view this report.


Recent News from (NASDAQ: GALT)

Data Collected by Exalenz Bioscience in Galectin Therapeutics' Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting
NORCROSS, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained in Galectin Therapeutics’ NASH-CX Phase 2 Clinical Trial...
Source: GlobeNewswire
Date: November, 05 2018 08:00
Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial
Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). The published response rate of KEYTRUDA alone is 33% in melanoma Providence Portland principal investigator, Dr. Brendan Curti, en...
Source: GlobeNewswire
Date: September, 20 2018 08:00
Midday Gainers / Losers (08/30/2018)
Gainers:   REIS +32% . SIG +28% . KTWO +26% . SHOS +24% . INSY +23% . CVM +19% . DXLG +18% . PARR +18% . ALRN +18% . GALT +16% . More news on: Reis, Inc, Signet Jewelers Limited, K2M Group Holdings, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 30 2018 12:36
NASH Cirrhosis: The Real NASH Epidemic
Introduction Cirrhosis of the liver threatens the lives of millions of people, and other than a risky, expensive, and temporary transplant, it has no treatment. This marks cirrhosis among those diseases with the greatest unmet medical needs. Healthy liver, left, versus cirrhotic liver...
Source: SeekingAlpha
Date: August, 28 2018 14:19
Galectin Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
NORCROSS, Ga., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s President and CEO, will present at the H.C. Wainwright 20...
Source: GlobeNewswire
Date: August, 28 2018 08:30
3 Marijuana Stocks & Biotech Stocks Capitalizing on Industry Momentum
CORAL GABLES, FL / ACCESSWIRE / August 21, 2018 / Once again the biotechnology sector is heading higher . The SPDR S&P Biotech ETF (XBI), iShares NASDAQ Biotechnology Index ETF (IBB) and Health Care SPDR ETF (XLV) are all green today. This continues to support the fact that biotech sto...
Source: ACCESSWIRE IA
Date: August, 21 2018 11:27
Your Daily Pharma Scoop: Motif Bio NDA Under Review, MiMedx Nixed, Biogen Halts
Stocks in News: MTFB, MDXG FDA accepts Motif Bio's NDA with priority review for Iclaprim Discussion : FDA accepted for filing the NDA of Motif Bio’s ( MTFB ) iclaprim. Iclaprim is a gram-positive investigational antibiotic, targeted for the treatment of acute bacterial skin and...
Source: SeekingAlpha
Date: August, 16 2018 09:08
Galectin Therapeutics - Distilling Noise And Focusing On Potential
Because of the information asymmetry between insiders and public investors, the amplitude for speculation in early stage biotech is enormous. Over the years, we have found that dividing the quest for an approximation of the truth into 3 buckets, has helped us make better decisions. 1 - Th...
Source: SeekingAlpha
Date: August, 15 2018 09:31
Galectin on go with late-stage study of GR-MD-02 in NASH; shares up 4%
Galectin Therapeutics ( GALT +4.2% ) has initiated preparations for a Phase 3 clinical trial assessing lead candidate GR-MD-02 in patients with NASH cirrhosis. More news on: Galectin Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: August, 14 2018 10:15
Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update
NORCROSS, Ga., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for its second fiscal quarter, which ended June 30, 2018, and provided a business update. These r...
Source: GlobeNewswire
Date: August, 14 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-135.255.055.29814.93156,820
2018-12-125.175.285.305.0846184,845
2018-12-115.095.135.224.94203,293
2018-12-104.975.005.154.85132,786
2018-12-075.064.985.15124.87123,021

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1323,70348,19449.1825Short
2018-12-1227,06751,95052.1020Short
2018-12-1130,96752,34859.1560Short
2018-12-1022,66936,76961.6525Short
2018-12-0732,66044,18773.9131Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GALT.


About Galectin Therapeutics Inc (NASDAQ: GALT)

Logo for Galectin Therapeutics Inc (NASDAQ: GALT)

Galectin is a clinical development stage biopharmaceutical company based in Norcross, Georgia, that is targeting fibrotic diseases and cancer with novel galectin inhibitor compounds. Galectins are a class of proteins made by many cells in the body and are important therapeutic targets because they are the mediators of fundamental biologic mechanisms in pathological processes. Galectin Therapeutics leverages its extensive scientific knowledge of galectins to advance their discovery program including research and discovery of new compounds. Through a relationship with a world class research program at the University of Georgia, the Company focuses on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role including cancer and inflammatory and fibrotic disorders.

 

 

 

Current Management

  • Peter G. Traber / CEO, President, CMO
  • Harold Shlevin / COO, Corporate Secretary
  • Jack Callicutt / CFO

Current Share Structure

  • Market Cap: $155,914,944 - 05/16/2018
  • Issue and Outstanding: 37,569,866 - 03/16/2018

 


Recent Filings from (NASDAQ: GALT)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 11 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 07 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 07 2018

 

 


Daily Technical Chart for (NASDAQ: GALT)

Daily Technical Chart for (NASDAQ: GALT)


Stay tuned for daily updates and more on (NASDAQ: GALT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GALT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GALT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GALT and does not buy, sell, or trade any shares of GALT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/